/PRNewswire/ BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will.
- GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China -
- BioLineRx to retain global rights to Motixafortide. | June 28, 2022
Form 6-K BioLineRx Ltd For: Jun 16 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.